Financing ·
Atossa Therapeutics reported second quarter 2026 financial results and provided a corporate update
ATOSAtossa Therapeutics, Inc.
Atossa Therapeutics reported second quarter 2026 financial results and provided a corporate update. The company raised $4.5 million in upfront gross proceeds from a registered direct offering of common stock and warrants, with potential additional proceeds up to $12 million upon full warrant exercise. Total operating expenses were $8.7 million for the three months ended June 30, 2026, compared to $9.0 million in the prior year period. The company also announced that enrollment in its Phase 2 EVANGELINE trial was completed and highlighted new preclinical data regarding (Z)-endoxifen's potential in rare pediatric diseases and breast cancer. Atossa Therapeutics is a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need.